Market reviews 2011

Market review on human pharmaceuticals 2011

Published 7 February 2012

According to statistics collected by Finnish Pharmaceutical Data Ltd, Finnish wholesale of human pharmaceuticals in 2011 totalled EUR 1,972 (1,926) million, up by 2% on the previous year.

Finland is the most important individual market for Orion, generating about one-quarter of the total net sales. Orion was able to increase its sales faster than the markets as a whole, so it strengthened its position as leader in marketing pharmaceuticals in Finland. According to statistics collected by Finnish Pharmaceutical Data Ltd, Orion’s wholesale of human pharmaceuticals in Finland in 2011 amounted to EUR 202 (192) million, up by 6% compared with the previous year. Orion’s market share was 10% (10%), which was nearly four percentage points higher than the second-largest company’s market share.

According to IMS Health pharmaceutical sales statistics, in the 12-month period ending in September 2011 the total sales of Parkinson’s drugs in the United States were down by 32% at USD 682 million (USD 1,001 million in the previous 12-month period). The decrease in in-market sales was due to commencement of generic competition in certain products. The five largest European markets for Parkinson’s disease drugs were Germany, the United Kingdom, France, Spain and Italy. In these countries, the combined sales of Parkinson’s drugs in the 12-month period ending in September 2011 totalled EUR 989 (1,018) million, and the average market decline was 3%.

The most important individual therapy area for Orion is still the treatment of Parkinson’s disease. Orion’s Parkinson’s drugs account for just under one-third of the Group’s net sales. Sales of Orion’s Parkinson’s drugs in the United States remained similar to the comparative period despite a clear decrease in the market as a whole. In Japan sales continued to grow well and clearly better than the market as a whole. According to IMS Health pharmaceutical sales statistics, in the 12-month period ending in September 2011, sales of Orion’s Parkinson’s drugs in the United States totalled USD 180 (180) million. Sales were similar to the previous year at a total of EUR 157 (156) million in the five largest markets in Europe, and up by 24% at EUR 53 (43) million in Japan. The market share of Orion’s Parkinson’s drugs was 26% in the United States, on average 16% in the five largest European markets and 11% in Japan.

According to IMS Health pharmaceutical sales statistics, sales of Orion’s Precedex® intensive care sedative (dexmedetomidine) were up by 37% at USD 194 million in the 12-month period ending in September 2011 (USD 142 million in the previous 12-month period). About four-fifths of the sales amounting to USD 153 (123) million were in the United States, where Precedex sales grew by 24%.

Published 25 October 2011

According to statistics collected by Finnish Pharmaceutical Data Ltd, Finnish wholesale of human pharmaceuticals in January–September 2011 totalled EUR 1,453 (1,415) million, up by 3% on the comparative period of the previous year.

Finland is the most important individual market for Orion, generating about one-quarter of the total net sales. Orion was able to increase its sales faster than the markets as a whole, so it strengthened its position as leader in marketing pharmaceuticals in Finland. According to statistics collected by Finnish Pharmaceutical Data Ltd, Orion’s wholesale of human pharmaceuticals in Finland in January–September amounted to EUR 150 (141) million, up by 6% compared with the corresponding period in the previous year. Orion’s market share in Finnish pharmaceutical markets was 10% (10%).

According to IMS Health pharmaceutical sales statistics, in the 12-month period ending in June 2011 the total sales of Parkinson’s drugs in the United States were down by 26% at USD 758 million (USD 1,025 million in the previous 12-month period). The decrease in in-market sales was due to commencement of generic competition in certain products. The five largest European markets for Parkinson’s disease drugs were Germany, the United Kingdom, France, Spain and Italy. In these countries, the combined sales of Parkinson’s drugs in the 12-month period ending in June 2011 totalled EUR 1,015 (991) million, and the average market growth was 2%.

The most important individual therapy area for Orion is still the treatment of Parkinson’s disease. Orion’s Parkinson’s drugs account for just under one-third of the Group’s net sales. Sales of Orion’s Parkinson’s drugs continued to grow well and clearly better than the market as a whole in the United States and in Japan. According to IMS Health pharmaceutical sales statistics, in the 12-month period ending in June 2011, sales of Orion’s Parkinson’s drugs in the United States totalled USD 181 (180) million. Sales were up by 2% at a total of EUR 158 (154) million in the five largest markets in Europe, and up by 32% at EUR 52 (39) million in Japan. The market share of Orion’s Parkinson’s drugs was 24% in the United States, on average 16% in the five largest European markets and 10% in Japan.

According to IMS Health pharmaceutical sales statistics, sales of Orion’s Precedex® intensive care sedative (dexmedetomidine) were up by 38% at USD 180 million in the 12-month period ending in June 2011 (USD 131 million in the previous 12-month period). About four-fifths of the sales amounting to USD 146 (113) million were in the United States, where Precedex sales grew by 29%.

Published 2 August 2011

According to statistics collected by Finnish Pharmaceutical Data Ltd, Finnish wholesale of human pharmaceuticals in January–June 2011 totalled EUR 967 (937) million, up by 3% on the comparative period of the previous year.

Finland is the most important individual market for Orion, generating about one-quarter of the total net sales. Orion was able to increase its sales faster than the markets as a whole, so strengthened its position as leader in marketing pharmaceuticals in Finland. According to statistics collected by Finnish Pharmaceutical Data Ltd, Orion’s wholesale of human pharmaceuticals in Finland in January–June amounted to EUR 100 (92) million, up by 8% compared with the corresponding period in the previous year. Orion’s market share was 10% (10%), which was over four percentage points higher than the second-largest company’s market share.

According to IMS Health pharmaceutical sales statistics, in the 12-month period ending in March 2011 the total sales of Parkinson’s drugs in the United States were down by 18% at USD 836 million (USD 1,022 million in the previous 12-month period). The decline of in-market sales was due to start of generic competition of some products. The five largest European markets for Parkinson’s disease drugs were Germany, the United Kingdom, France, Spain and Italy. In these countries, the combined sales of Parkinson’s drugs in the 12-month period ending in March 2011 totalled EUR 1,035 (962) million, and the average market growth was 8%.

The most important individual therapy area for Orion is still the treatment of Parkinson’s disease. Orion’s Parkinson’s drugs account for just under one-third of the Group’s net sales. Sales of Orion’s Parkinson’s drugs continued to grow well and clearly better than the market as a whole in the United States and in Japan. According to IMS Health pharmaceutical sales statistics, in the 12-month period ending March 2011, sales of Orion’s Parkinson’s drugs were up by 1% at USD 180 (178) million in the United States, up by 4% at a total of EUR 158 (152) million in the five largest markets in Europe, and up by 43% at EUR 50 (35) million in Japan. The market share of Orion’s Parkinson’s drugs was 22% in the United States, on average 15% in the five largest European markets and 10% in Japan.

According to IMS Health pharmaceutical sales statistics, sales of Orion’s Precedex® intensive care sedative (dexmedetomidine) were up by 51% at USD 175 million in the 12-month period ending March 2011 (USD 116 million in the previous 12-month period). About four-fifths of the sales amounting to USD 141 (99) million were in the United States, where Precedex® sales grew by 42%.

Published 27 April 2011

According to statistics collected by Finnish Pharmaceutical Data Ltd, Finnish wholesale of human pharmaceuticals in January–March 2011 totalled EUR 474 (464) million, up by 2% on the comparative period of the previous year.

Finland is the most important individual market for Orion, generating about one-quarter of the total net sales. Orion was able to increase its sales faster than the markets as a whole, so strengthened its position as leader in marketing pharmaceuticals in Finland. According to statistics collected by Finnish Pharmaceutical Data Ltd, Orion’s wholesale of human pharmaceuticals in Finland in January–March amounted to EUR 49 (47) million, up by 4% compared with the previous year. Orion’s market share was 10% (10%), which was over four percentage points higher than the second-largest company’s market share.

According to IMS Health pharmaceutical sales statistics, in the 12-month period ending in December 2010 the total sales of Parkinson’s drugs in the United States were down by 7% at USD 928 million (USD 1,001 million in the previous 12-month period). The five largest European markets for Parkinson’s disease drugs were Germany, the United Kingdom, France, Spain and Italy. In these countries, the combined sales of Parkinson’s drugs in the 12-month period ending in December totalled EUR 1,017 (907) million, and the average market growth was 12%.

The most important individual therapy area for Orion is still the treatment of Parkinson’s disease. Orion’s Parkinson’s drugs account for just under one-third of the Group’s net sales. Sales of Orion’s Parkinson’s drugs continued to grow well and clearly faster than the market as a whole in the United States and in Japan. According to IMS Health pharmaceutical sales statistics, in the 12-month period ending December 2010, sales of Orion’s Parkinson’s drugs were up by 3% at USD 181 (175) million in the United States, up by 6% at a total of EUR 158 (149) million in the five largest markets in Europe, and up by 43% at EUR 47 (33) million in Japan. The market share of Orion’s Parkinson’s drugs was 20% in the United States, on average 16% in the five largest European markets and 10% in Japan.

According to IMS Health pharmaceutical sales statistics, sales of Orion’s Precedex® intensive care sedative (dexmedetomidine) were up by 59% at USD 160 million in the 12-month period ending December 2010 (USD 101 million in the previous 12-month period). About four-fifths of the sales amounting to USD 132 (85) million were in the United States, where Precedex® sales grew by 55%.